Skip to main content

Market Overview

Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know

Share:

JPMorgan’s Anupam Rama believes data from the two phase 3 trials of fostamatinib would be positive and that Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s stock could see 90-150 percent upside if that was the case.

The analyst upgraded the rating on the company from Neutral to Overweight, with a $5 price target.

Rama also pointed out that in the event that the data was negative, the worst-case scenario would a 55 percent downside to the stock, from its current levels.

Data Expectations

Top-line Phase 3 data for fostamatinib in idiopathic thrombocytopenic purpura (ITP) is expected in mid-2016, with a potential NDA filing in early-2017. The analyst estimates worldwide peak sales for the drug at $360 million.

Rama mentioned that physician feedback for the earlier Phase 2 data had been positive, highlighting robust early proof of concept.

“We view ~20 percent improvement in sustained response over placebo as the beatable / clinically meaningful phase 3 activity benchmark,” Rama stated, while adding, “Based on physician commentary, we do not have any over-arching safety concerns.”

The analyst believes that there is high probability of success for the ongoing Phase 3 trials, and noted that topline fostamatinib data, expected in mid-2016, could be a “transformative catalyst” for Rigel Pharmaceuticals.

Latest Ratings for RIGL

DateFirmActionFromTo
Feb 2021HC Wainwright & Co.MaintainsBuy
Nov 2020JP MorganDowngradesOverweightNeutral
Aug 2020CitigroupMaintainsBuy

View More Analyst Ratings for RIGL

View the Latest Analyst Ratings

 

Related Articles (RIGL)

View Comments and Join the Discussion!

Posted-In: Anupam Rama J.P. MorganAnalyst Color Long Ideas Upgrades Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com